NCT07276321 Preliminary Efficacy of an mHealth Intervention in West Africa
| NCT ID | NCT07276321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Schizophrenic Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-11-03 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We are conducting a pilot feasibility and preliminary efficacy trial of a digital intervention for serious mental illness in West Africa. Participants will be recruited from a large psychiatric hospital in Ghana and randomized into one of three study conditions: 1) Treatment as usual; 2) FOCUS intervention; 3) G-FOCUS intervention.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years of age or older 2. Speaks English 3. Outpatient receiving care at Accra Psychiatric Hospital 4. Diagnosis of Schizophrenic Spectrum Disorder 5. Owns a mobile device capable of downloading smartphone applications Exclusion Criteria: 1. Hearing, vision, or motor impairment that would hamper their ability to participate in data collection 2. Serious intellectual or developmental disability that would hamper their ability to participate in data collection
Contact & Investigator
Dror Ben-Zeev, PhD
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT07276321 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Schizophrenic Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07276321 currently recruiting?
Yes, NCT07276321 is actively recruiting participants. Contact the research team at beaulia@uw.edu for enrollment information.
Where is the NCT07276321 trial being conducted?
This trial is being conducted at Accra, Ghana.
Who is sponsoring the NCT07276321 clinical trial?
NCT07276321 is sponsored by University of Washington. The principal investigator is Dror Ben-Zeev, PhD at University of Washington. The trial plans to enroll 150 participants.